Idiopathic parafoveal telangiectasis (IPT) is a kind of disease which is rare, with potential clinical blindness, sometimes confused with some other macular diseases, and its pathogenesis is not yet clear. According to the different classification, main clinical manifestations are macular telangiectasis, leakage, or neovascularization, and visual loss resulted from gradual retinal atrophy. The clinical characteristic in different stages of this disease, progress of multimodal fundus imaging technology in diagnosis and recent development of treatment methods were reviewed in this paper.
毛蕾,宫媛媛. 特发性旁中心凹毛细血管扩张症诊治进展[J]. 中华眼视光学与视觉科学杂志, 2016, 18(6): 377-380.
Mao Lei,Gong Yuanyuan. The development of the diagnosis and treatment of parafoveal telangiectasis. Chinese Journal of Optometry Ophthalmology and Visual science, 2016, 18(6): 377-380.
Spaide RF, Klancnik JM Jr, Cooney MJ. Retinal vascular layers in macular telangiectasia type 2 imaged by optical coherence tomographic angiography[J]. JAMA Ophthalmol,2015,133(1):66-73. DOI:10.1001/jamaophthalmol.2014.3950.
[2]
Wu L, Evans T, Arevalo JF. Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2)[J]. Surv Ophthalmol,2013,58(6):536-559. DOI:10.1016/j.survophthal.2012.11.007.
[3]
Chen JJ, Sohn EH, Folk JC, et al. Decreased macular thickness in nonproliferative macular telangiectasia type 2 with oralcarbonic anhydrase inhibitors[J]. Retina,2014,34(7):1400-1406. DOI:10.1097/IAE.0000000000000093.
[4]
Toklu Y, Raza S, Anayol MA, et al. Comparison between efficacy of Triamcinolone Acetonide and Bevacizumab in a case with type 2A idiopathic parafoveal telangiectasia[J]. Turk J Ophthalmol,2011,41:6-9. DOI:10.4274/tjo.41.02.
[5]
Charbel Issa P, Finger RP, Helb HM, et al. A new diagnostic approach in patients with type 2 macular telangiectasia: Confocal reflectance imaging[J]. Acta Ophthalmol,2008,86(4):464-465. DOI:10.1111/j.1600-0420.2007.01041.
[6]
Bottoni F, Eandi CM, Pedenovi S, et al. Integrated clinical evaluation of Type 2A idiopathic juxtafoveolar retinal telangiectasis[J]. Retina,2010,30(2):317-326. DOI:10.1097/IAE.0b013e3181b9f11e.
[7]
Charbel Issa P, Berendschot TT, Staurenghi G, et al. Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia[J]. Invest Ophthalmol Vis Sci,2008,49(3):1172-1177. DOI:10.1167/iovs.07-0636.
[8]
Cohen SM, Cohen ML, El-Jabali F, et al. Optical coherenc tomography findings in nonproliferative group 2a idiopathic juxtafoveal retinal telangiectasis[J]. Retina,2007,27(1):59-66. DOI:10.1097/01.iae.0000256663.94734.
[9]
Balaskas K, Leung I, Sallo FB, et al. Associations between autoflurescence abnormalities and visual acuity in idiopathic macular telangitasia type 2[J]. Retina,2014,34(8):1630-1636. DOI:10.1097/IAE.0000000000000110.
[10] Kovach JL, Rosenfeld PJ. Bevacizumab(Avastin) therapy for idiopathic macular telangiectasia type II[J]. Retina,2009,29(1):27-32. DOI:10.1097/IAE.0b013e31818ba9de.
[11] Gamulescu MA, Walter A, Sachs H, et al.Bevacizumab in the treatment of idiopathic macular telangiectasia[J]. Graefes Arch Clin Exp Ophthalmol,2008,246(8):1189-1193. DOI:10.1007/s00417-008-0795-6.
[12] Rouvas A, Malamos P, Douvali M, et al. Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia[J]. Clin Ophthalmol,2013,7:1357-1362. DOI:10.2147/OPTH.S44109.
[13] Charbel Issa P, Troeger E, Finger R, et al. Structure-function correlation of the human central retina[J]. PLoS One,2010,5(9):e12864(1-8). DOI:10.1371/journal.pone.0012864.
[14] Fallano KA, Ibrahim M, Nguyen QD, et al. Progressive changes from idiopathic macular telangiectasia seen with spectral domain optical coherence tomography[J]. Can J Ophthalmol,2010,45(6):649-650. DOI:10.3129/i10-038.
[15] Dave V, Chhablani J, Narayanan R. Different treatment modalities for choroidal neovascularization in two eyes of one patient with bilateral type 2A parafoveal telangiectasia[J]. Indian J Ophthalmol,2013,61(7):353-355. DOI:10.4103/0301-4738.99851.
[16] Eandi CM, Ober MD, Freund KB, et al. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study[J]. Retina,2006,26(7):780-785. DOI:10.1097/01.iae.0000244262. 91018.
[17] Sigler EJ, Randolph JC, Calzada JI, et al. Pars plana vitrectomy with internal limiting membrane removal in type 2 idiopathic macular telangiectasia[J]. Retin Cases Brief Rep,2013,7(4):380-385. DOI:10.1097/ICB.0b013e318297f69a.
[18] Chew EY, Clemons TE, Peto T, et al. Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial[J]. Am J Ophthalmol,2015,159(4):659-666.e1. DOI:10.1016/j.ajo.2014.12.013.